Revenue and Financial Performance - Revenue for fiscal year 2024 was $2,755.0 million, an increase of $4.5 million, or less than 1%, compared to fiscal year 2023[146]. - Diagnostics segment revenue increased by $42.7 million, or 3%, to $1,500.9 million, driven by growth in immunodiagnostics and reproductive health[157]. - Life Sciences segment revenue decreased by $38.2 million, or 3%, to $1,254.1 million, primarily due to a decline in instruments and reagents revenue[154]. - Total revenue for the year ended December 29, 2024, was $2.755 billion, a slight increase from $2.751 billion in 2023[220]. - Product revenue decreased to $2.338 billion in 2024 from $2.416 billion in 2023, while service revenue increased to $416.8 million from $334.7 million[220]. - Operating income from continuing operations rose to $346.7 million in 2024, compared to $300.6 million in 2023, reflecting a 15.4% increase[220]. - Net income for 2024 was $270.4 million, a significant decrease from $693.1 million in 2023, primarily due to losses from discontinued operations[220]. - Basic earnings per share from continuing operations increased to $2.31 in 2024 from $1.44 in 2023[220]. Expenses and Margins - Consolidated gross margin decreased by 16 basis points to 55.8% in fiscal year 2024, attributed to an unfavorable product mix and higher product costs[147]. - Consolidated operating margin increased by 166 basis points to 16.5% in fiscal year 2024, supported by productivity initiatives and cost containment[144]. - Research and development expenses decreased by $19.7 million, or 9%, to $196.8 million, representing 7.1% of revenue[149]. - Selling, general and administrative expenses decreased by $28.5 million, or 3%, to $994.1 million, accounting for 36.1% of revenue[148]. Cash Flow and Financing Activities - Net cash provided by continuing operations increased to $665.0 million in fiscal year 2024, up from $279.4 million in fiscal year 2023, reflecting higher income and less cash used for working capital[165]. - The company reported net cash used in financing activities of $1,128.2 million for fiscal year 2024, an increase of $181.1 million compared to $947.1 million in fiscal year 2023[168]. - The company authorized a new stock repurchase program for up to $1.0 billion, replacing the previous program, with $857.2 million remaining available for repurchases as of December 29, 2024[175]. - The company received cash proceeds of $2.27 billion from divestitures, with an additional $75 million expected from the Brand Sale and up to $150 million contingent on future sales by the Purchaser[181]. Tax and Interest Expenses - The effective tax rate for fiscal year 2024 was 10.5%, compared to 1.9% in fiscal year 2023[151]. - Interest and other expense, net, decreased significantly from $117.6 million in fiscal year 2023 to $30.6 million in fiscal year 2024[150]. - The total provision for income taxes for continuing operations was $33.1 million in 2024, compared to $3.5 million in 2023[295]. Assets and Liabilities - As of December 29, 2024, the company had cash and cash equivalents of $1,163.4 million, with $1.5 billion of borrowing capacity available under its senior unsecured revolving credit facility[173]. - Total assets decreased to $12.392 billion in 2024 from $13.565 billion in 2023[226]. - Total stockholders' equity decreased to $7.667 billion in 2024 from $7.873 billion in 2023[226]. - The company’s total liabilities decreased from $4,951,018 thousand in 2023 to $5,609,212 thousand in 2024[230]. Goodwill and Intangible Assets - The company's goodwill balance as of December 29, 2024, was $6.5 billion, with $4.3 billion allocated to the Life Sciences reporting unit[214]. - The fair value of the Life Sciences reporting unit exceeded its carrying value by more than 10% but less than 20% as of November 1, 2024[215]. - Total amortization expense related to amortizable intangible assets was $359.4 million in fiscal year 2024, with estimated future amortization expenses projected to decrease over the next five years[317]. Strategic Initiatives and Future Outlook - The company anticipates an increase in capital expenditures in fiscal year 2025, focusing on enhancing digital capabilities and product innovations[172]. - The company plans to fund its strategic initiatives through a combination of existing cash reserves and internally generated funds from continuing operations[172]. - The company expects to recognize substantially all deferred revenue within 12 months of the balance sheet date[287]. Discontinued Operations - For fiscal year 2024, the company recognized a loss of $12.7 million from discontinued operations, compared to income of $513.6 million in fiscal year 2023[162]. - The operating loss from discontinued operations for the fiscal year ended December 29, 2024, was $37.9 million, compared to an operating income of $68.4 million in 2023[292]. Pension and Benefit Obligations - The company recognized a net periodic pension cost of $10,314,000 for fiscal year 2024, compared to $20,062,000 in 2023[329]. - Accumulated benefit obligations for Non-U.S. increased to $212,120, while U.S. obligations rose to $90,293 as of December 29, 2024[332]. - The discount rate for Non-U.S. plans was 4.19% and for U.S. plans was 5.71% as of year-end measurement[332].

Core Viewpoint - Revvity, Inc. reported strong fourth-quarter 2024 results with adjusted EPS of $1.42, exceeding estimates and showing a year-over-year improvement of 13.6% [1][2] Financial Performance - GAAP EPS from continuing operations was 78 cents, up from 64 cents in the prior year, including 5 cents from discontinued operations [2] - Total revenues reached $729.3 million, reflecting a 4.8% year-over-year increase, but slightly missing the Zacks Consensus Estimate by 0.1% [3] Segment Analysis - Life Sciences segment revenues were $336 million, up 5% year-over-year, with adjusted operating income of $131 million, an 11% increase [4] - Diagnostics segment revenues totaled $393 million, a 4.5% year-over-year increase, with organic growth of 6% [4] Margin and Expense Analysis - Selling, general and administrative expenses decreased by 4.8% to $244.3 million, while research and development expenses were $49.2 million, down 0.8% [6] - Adjusted operating income improved by 15.4% to $221.3 million, with an adjusted operating margin of 28.3%, expanding by 280 basis points [6] Cash Flow and Financial Position - The company ended Q4 2024 with cash and cash equivalents of $1.16 billion, down from $1.23 billion in the previous quarter [7] - Net cash provided by operating activities was $174.2 million, compared to a net cash used of $196.6 million in the year-ago quarter [7] 2025 Guidance - For 2025, Revvity expects adjusted EPS in the range of $4.90-$5.00 and revenues between $2.80-$2.85 billion, with Zacks Consensus Estimates at $4.97 and $2.87 billion respectively [8]

Core Insights - Revvity (RVTY) reported revenue of $729.37 million for the quarter ended December 2024, reflecting a year-over-year increase of 4.8% [1] - The company's EPS was $1.42, up from $1.25 in the same quarter last year, surpassing the consensus estimate of $1.36 by 4.41% [1] - The revenue fell slightly short of the Zacks Consensus Estimate of $730.06 million, resulting in a surprise of -0.10% [1] Financial Performance Metrics - Organic revenue growth in Life Sciences was 5%, exceeding the average estimate of 2.7% from three analysts [4] - Total organic revenue growth was reported at 6%, compared to the average estimate of 4.1% [4] - Organic revenue growth in Diagnostics was 6%, surpassing the average estimate of 5.5% [4] Sales Performance - Net Sales in Life Sciences reached $336.34 million, slightly below the average estimate of $344.79 million, but still showing a year-over-year increase of 5.2% [4] - Net Sales in Diagnostics amounted to $393.24 million, exceeding the average estimate of $385.63 million, with a year-over-year growth of 4.5% [4] Stock Performance - Revvity's shares have returned +13.3% over the past month, outperforming the Zacks S&P 500 composite's +2.9% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Fourth Quarter 2024 Financial Performance - Adjusted revenue reached $730 million, a 5% year-over-year increase[15] - Organic revenue growth was 6%, with no impact from M&A and a negative 1% impact from foreign exchange[15] - Adjusted operating margin was 30.3%, a 280 basis points increase year-over-year[15] - Adjusted EPS was $1.42, a 14% increase year-over-year[15] - Free cash flow was $151 million for the quarter and $578 million for the full year[15] - Adjusted gross margin was 61.4%, a 120 basis points increase year-over-year[15] Full Year 2024 Financial Performance - Adjusted revenue was $2756 million, flat year-over-year[17] - Organic revenue growth was 1%, with no impact from M&A or foreign exchange[17] - Adjusted operating margin was 28.3%, a 30 basis points increase year-over-year[17] - Adjusted EPS was $4.90, a 6% increase year-over-year[17] - Free cash flow was $578 million, representing 96% of adjusted net income[17] - Adjusted gross margin was 61.3%, a 10 basis points decrease year-over-year[17] 2025 Financial Guidance - Revenue is projected to be between $2.80 billion and $2.85 billion, representing a reported growth of 1.5% to 3.5%[27] - Organic revenue growth is expected to be between 3% and 5%, with a negative 1.5% impact from foreign exchange and no impact from M&A[27]

Financial Data and Key Metrics Changes - The company generated total adjusted revenues of $730 million in Q4 2024, resulting in 6% organic growth, which was above expectations [18] - For the full year, total adjusted revenue was $2.76 billion, with 1% organic growth [19] - Adjusted EPS for Q4 was $1.42, exceeding guidance by $0.04, and for the full year, adjusted EPS was $4.90, representing 5% growth year over year [21][22] Business Line Data and Key Metrics Changes - Life Sciences segment generated $336 million in Q4, up 5% on both a reported and organic basis, but down low single digits for the full year [25] - Diagnostics segment generated $393 million in Q4, up 4% on a reported basis and 6% on an organic basis, with 4% organic growth for the full year [27] - The Life Sciences instruments revenue was down high single digits in Q4 and down low double digits for the full year [25] Market Data and Key Metrics Changes - In Q4, organic revenue growth was 5% in Life Sciences and 6% in Diagnostics, with mid single digits growth in the Americas, low single digits in Europe, and mid single digits in Asia, particularly high single digits in China [23] - For the full year, China experienced low single digit growth in diagnostics and mid teens growth in life sciences, but overall, China declined in the low single digits organically [24] Company Strategy and Development Direction - The company plans to step up strategic internal investments in 2025, expecting organic growth to improve [9][31] - A new Life Sciences Solutions business unit will be established, representing approximately 85% of the Life Sciences segment, reflecting a re-segmentation of the Applied Genomics business [14] - The company aims for adjusted operating margin expansion of 20 to 40 basis points in 2025, despite increased investments [31] Management's Comments on Operating Environment and Future Outlook - Management noted that while demand trends have stabilized, the pace of recovery remains uncertain, leading to a cautious outlook for 2025 [39] - The company expects total organic growth in 2025 to be in the range of 3% to 5%, with balanced growth expected throughout the year [30] - Management expressed optimism about the potential for recovery in the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Other Important Information - The company repurchased $185 million worth of shares in Q4, bringing total buyback activity for 2024 to $370 million [22] - Free cash flow for Q4 was $151 million, with a full year total of $578 million, equating to 96% conversion of adjusted net income [22] Q&A Session Summary Question: Insights on key end markets and recovery areas - Management acknowledged a path to recovery but emphasized uncertainty in the pace of return to normalcy, with diagnostics and software businesses showing signs of improvement while instrumentation remains a concern [39][40] Question: Guidance for China and stimulus impact - Management expects China to align with company growth averages, with modest stimulus impact anticipated [41][42] Question: Segment outlooks relative to overall guidance - Diagnostics is expected to perform above the company average, while Life Sciences is projected to be in the low single digits [46][47] Question: Expectations for reagents growth - Management indicated that the reagents business is gaining market share and is expected to grow in mid single digits for fiscal 2025 [48][50] Question: Q1 guidance and margin visibility - Management noted that Q1 margins are typically below the full year average, with a similar cadence expected as in 2024 [54] Question: Applied Genomics recovery expectations - Management expressed optimism about the recovery of the Applied Genomics business as it transitions to the Life Sciences Solutions portfolio [63] Question: FX impact on margins - Management clarified that FX does not have a material impact on operating margins [66] Question: Strategic investments for 2025 - Management highlighted increased investments in digital capabilities and expanding sales channels as part of their strategy for 2025 [70]

Company Performance - Revvity (RVTY) reported quarterly earnings of $1.42 per share, exceeding the Zacks Consensus Estimate of $1.36 per share, and up from $1.25 per share a year ago, representing an earnings surprise of 4.41% [1] - The company posted revenues of $729.37 million for the quarter ended December 2024, slightly missing the Zacks Consensus Estimate by 0.10%, but up from $695.9 million year-over-year [2] - Over the last four quarters, Revvity has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Market Performance - Revvity shares have increased approximately 13.7% since the beginning of the year, outperforming the S&P 500's gain of 3.2% [3] - The current consensus EPS estimate for the upcoming quarter is $1.11 on revenues of $678.51 million, and for the current fiscal year, it is $4.97 on revenues of $2.87 billion [7] Industry Outlook - The Medical Services industry, to which Revvity belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Revvity's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Financial Performance - Fourth quarter 2024 GAAP revenue was $729 million, representing a 5% increase year-over-year, with organic growth of 6%[3][4][8] - Fourth quarter 2024 adjusted earnings per share from continuing operations was $1.42, compared to $1.25 in the same period last year[4][8] - Full year 2024 GAAP revenue was $2,755 million, slightly up from $2,751 million in 2023[5][6] - Full year 2024 adjusted earnings per share from continuing operations was $4.90, an increase from $4.65 in 2023[6] - The company reported a net income of $94.6 million for the fourth quarter 2024, compared to $78.6 million in the same period last year[21] - Net income for the three months ended December 29, 2024, was $94,645,000, compared to $78,563,000 for the same period in 2023, representing a year-over-year increase of 20.5%[29] - Income from continuing operations for the twelve months ended December 29, 2024, was $283,071,000, up from $179,503,000 in 2023, reflecting a growth of 57.7%[29] Operating Income and Margins - Fourth quarter 2024 GAAP operating income from continuing operations was $119 million, up from $77 million in the same period last year[3][4] - Full year 2024 GAAP operating profit margin from continuing operations was 12.6%, compared to 10.9% in 2023[5] - Fourth quarter 2024 adjusted operating income was $221 million, compared to $192 million in the same period last year[4] - Reported operating income from continuing operations for the twelve months ended December 29, 2024, was $346,741 thousand, compared to $300,562 thousand for the same period in 2023, an increase of about 15%[24] - Operating margin (OP%) improved to 30.3% in Q4 2024 from 27.5% in Q4 2023[24] Revenue by Segment - Life Sciences segment revenue for Q4 2024 was $336,340 thousand, up from $319,691 thousand in Q4 2023, representing a growth of approximately 5.3%[24] - Diagnostics segment revenue for Q4 2024 was $393,240 thousand, an increase from $376,419 thousand in Q4 2023, reflecting a growth of about 4.5%[24] - The company reported a 5% organic revenue growth in the Life Sciences segment for the three months ended December 29, 2024[31] - The Diagnostics segment achieved an organic revenue growth of 4% for the three months ended December 29, 2024, despite a 1% negative impact from foreign exchange rates[31] Guidance and Future Outlook - The company initiated full year 2025 guidance, forecasting total revenue of $2.80-$2.85 billion and adjusted earnings per share of $4.90-$5.00[11][12] - The company plans to continue focusing on operational efficiency and strategic investments to drive future growth[33] Cash Flow and Assets - The company reported a net cash provided by operating activities of continuing operations of $664,955,000 for the twelve months ended December 29, 2024, compared to $279,387,000 in 2023, indicating a significant increase of 138.4%[29] - Cash, cash equivalents, and restricted cash at the end of the period were $1,164,452,000, an increase from $914,373,000 at the end of the previous year[30] - Total current assets decreased to $2,349,608 thousand in Q4 2024 from $3,001,091 thousand in Q4 2023, a decline of approximately 22%[26] - Cash and cash equivalents increased to $1,163,396 thousand in Q4 2024 from $913,163 thousand in Q4 2023, showing a growth of about 27%[26] - The company experienced a net cash used in financing activities of continuing operations amounting to $1,128,235,000 for the twelve months ended December 29, 2024, compared to $947,121,000 in 2023[30] Non-GAAP Measures - The company uses "adjusted operating income" to refer to GAAP operating income, which includes revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules[40] - "Free cash flow" is defined as net cash provided by operating activities of continuing operations, less capital expenditures, plus proceeds from capital disposals[41] - "Adjusted net income" excludes various costs such as amortization of intangible assets and significant litigation matters, reflecting a more accurate performance of ongoing operations[42] - "Adjusted earnings per share" from continuing operations is calculated by excluding costs related to debt extinguishment and asset impairments, among others[43] - Management excludes amortization of intangible assets from non-GAAP measures as it does not reflect ongoing operational performance[44] - Significant expenses related to acquisitions and divestitures are excluded from non-GAAP measures to provide a clearer view of operational performance[45] - The company does not consider asset impairments and restructuring charges as reflective of ongoing operations, thus excluding them from adjusted measures[46] - Non-GAAP financial measures are not considered superior to GAAP financial statements and should be viewed in conjunction with them[47] - These non-GAAP measures are used by management to evaluate operating performance and benchmark results against peers[48]

Revvity, Inc. (RVTY) is slated to report fourth-quarter 2024 results on Jan. 31, before market open.In the last reported quarter, the company delivered an earnings surprise of 13.27%. RVTY’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.55%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q4 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $730.1 million, up 4.9% from the prior-year quarter’s level. The consensus mar ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Revvity (RVTY) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 31, 2025, might help the stock move higher if these key numbers are better than expe ...

Company Overview - Revvity has a market capitalization of $13.86 billion with an earnings yield of 4.4%, which is favorable compared to the industry's 3.7% [1] - The company delivered an earnings surprise of 13.3% in the last reported quarter [1] FDA Approval and Product Development - Revvity received FDA 510(k) clearance for EUROIMMUN's automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone, making it the only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma [2] - The assay is processed on Revvity's random-access iSYS or i10 instruments, offering quick turnaround times, high-throughput testing, minimal technician training, and high accuracy [4] - The assay is expected to enhance diagnostic capabilities for conditions like hypogonadism and impotence by providing direct measurement of free testosterone levels in a single test [4] - Management believes the FDA clearance will expand the FDA-cleared menu for EUROIMMUN's ChLIA automation solutions, serving a diverse patient pool across all demographics [5] - Results on EUROIMMUN's ChLIA platforms are expected to be rapidly available, with the first result available in 48 minutes and an estimated throughput of nearly 60 tests per hour [15] Market and Industry Prospects - The global testosterone test market was valued at $100 million in 2023 and is anticipated to reach $208.1 million by 2034, growing at a CAGR of 6.9% [6] - Factors driving the market include rising awareness about hormonal disorders and increasing prevalence of male infertility [6] - The latest FDA clearance is expected to be a significant milestone for Revvity, boosting its business in this growing market [6] Recent Developments - In November 2024, Revvity expanded its collaboration with Genomics England to advance critical genomic initiatives across the UK [7] - The company reported solid revenue growth in its third-quarter 2024 results, both on a reported and organic basis [7] Stock Performance - Following the FDA approval announcement, Revvity's shares lost nearly 2.2% by Friday's closing [3] - Historically, the company has gained a top-line boost from regulatory achievements and product launches, but the stock declined overall despite the latest FDA approval [3] - Over the past year, Revvity's shares have gained 2.8%, outperforming the industry's 9.8% decline, while the S&P 500 gained 23% [9] Comparison with Industry Peers - Cardinal Health (CAH) has a Zacks Rank 2 (Buy) with an estimated long-term growth rate of 10.5% and an average earnings surprise of 11.2% over the trailing four quarters [11] - ResMed (RMD) has a Zacks Rank 2 with an estimated long-term growth rate of 14.8% and an average earnings surprise of 6.4% over the trailing four quarters [12] - Boston Scientific (BSX) has a Zacks Rank 2 with an estimated long-term growth rate of 13.8% and an average earnings surprise of 8.3% over the trailing four quarters [12] - Cardinal Health's shares have gained 14.9% compared to the industry's 2.1% growth, ResMed has gained 34.5% compared to the industry's 7.8% growth, and Boston Scientific has rallied 58.3% compared to the industry's 7.8% growth over the past year [11][12][13]